Heron Therapeutics, Inc. (HRTX) Earns “Buy” Rating from Noble Financial
HRTX has been the topic of a number of other reports. Mizuho reaffirmed a buy rating and issued a $28.00 target price on shares of Heron Therapeutics in a research report on Tuesday, November 7th. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the company a buy rating in a research report on Friday, October 20th. Cowen and Company reaffirmed a buy rating and issued a $40.00 target price on shares of Heron Therapeutics in a research report on Monday, November 6th. BidaskClub raised shares of Heron Therapeutics from a sell rating to a hold rating in a research report on Saturday, August 26th. Finally, Aegis reaffirmed a buy rating and issued a $33.00 target price on shares of Heron Therapeutics in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. Heron Therapeutics has a consensus rating of Buy and a consensus target price of $28.36.
Heron Therapeutics (HRTX) opened at $15.65 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12. Heron Therapeutics has a 52-week low of $12.21 and a 52-week high of $20.85.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million for the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. equities research analysts forecast that Heron Therapeutics will post -3.41 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Heron Therapeutics, Inc. (HRTX) Earns “Buy” Rating from Noble Financial” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/11/15/heron-therapeutics-inc-hrtx-earns-buy-rating-from-noble-financial.html.
Institutional investors have recently modified their holdings of the business. Legal & General Group Plc grew its position in Heron Therapeutics by 13.9% during the 1st quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,098 shares during the last quarter. Quantbot Technologies LP lifted its stake in shares of Heron Therapeutics by 2,619.6% in the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after acquiring an additional 12,024 shares during the period. Trexquant Investment LP acquired a new stake in shares of Heron Therapeutics in the 3rd quarter worth $206,000. Jane Street Group LLC acquired a new stake in shares of Heron Therapeutics in the 3rd quarter worth $223,000. Finally, HighTower Advisors LLC lifted its stake in shares of Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 1,700 shares during the period.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.